Orthofix Medical Inc. (OFIX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Orthofix Medical Inc. (OFIX) Healthcare & Pipeline Overview

Orthofix Medical Inc. develops, manufactures, and distributes orthopedic and spine solutions globally. Operating through Global Spine and Global Orthopedics segments, the company provides bone growth stimulators, spinal implants, and fracture repair devices. With a $405M market cap, Orthofix serves hospitals and physicians through direct sales and distributors.

What Is the Investment Thesis for OFIX?

Orthofix Medical Inc. presents a mixed investment thesis. The company's gross margin of 69.0% indicates strong pricing power and efficient operations. However, a negative profit margin of -7.3% raises concerns about profitability and cost management. Growth catalysts include expanding its product portfolio and market reach in both the Global Spine and Global Orthopedics segments. The company's focus on regenerative non-tissue biologic solutions also provides a growth avenue. Potential risks include increased competition in the medical device industry and the need to maintain regulatory compliance across multiple international markets. Investors should closely monitor Orthofix's ability to improve profitability and capitalize on growth opportunities.

Based on FMP financials and quantitative analysis

OFIX Key Highlights

Market Cap of $405M reflects the company's current valuation in the medical device market.

• Gross Margin of 69.0% indicates strong pricing power and efficient manufacturing processes.
• Profit Margin of -7.3% signals potential challenges in achieving profitability and managing operating expenses.
• Beta of 0.82 suggests the stock is less volatile than the overall market.
• No Dividend Yield indicates that the company is reinvesting earnings for growth rather than distributing them to shareholders.

Who Are OFIX's Competitors?

OFIX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OFIX's Key Strengths?

Strong gross margin of 69.0%.

• Established presence in the spine and orthopedics markets.
• Proprietary technologies in bone growth stimulation and regenerative biologics.
• Global distribution network.

What Are OFIX's Weaknesses?

Negative profit margin of -7.3%.

• High operating expenses.
• Dependence on regulatory approvals.
• Limited market share compared to larger competitors.

What Could Drive OFIX Stock Higher?

Launch of new regenerative non-tissue biologic solutions.

• Expansion of the Global Spine segment through new product introductions.
• Strategic acquisitions to expand product portfolio and geographic reach.
• Investment in research and development to create innovative products.

What Are the Key Risks for OFIX?

Financial-distress signal — its Altman Z-Score of 1.13 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-13.4%) — the business is not currently generating profit on shareholder capital.
• Increased competition from larger medical device companies.
• Pricing pressures from healthcare providers.
• Changes in regulatory requirements.
• Product liability claims.
• Negative profit margin impacting financial stability.

What Are the Growth Opportunities for OFIX?

• Expansion of Global Spine Segment: Orthofix can expand its Global Spine segment by introducing new motion preservation and fixation implant products. The market for spinal implants is projected to reach $12.9 billion by 2028, driven by an aging population and increasing prevalence of spinal disorders. By investing in research and development, Orthofix can capture a larger share of this market and drive revenue growth. Timeline: Ongoing.
• Growth in Regenerative Biologics: The market for regenerative medicine is growing rapidly, with a focus on non-tissue biologic solutions. Orthofix can capitalize on this trend by expanding its portfolio of regenerative products derived from synthetic materials. This includes developing new applications for these materials in spinal and orthopedic procedures. The regenerative medicine market is expected to reach $55 billion by 2027. Timeline: Ongoing.
• Strategic Acquisitions: Orthofix can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or market access can accelerate growth and enhance Orthofix's competitive position. Potential acquisition targets include companies specializing in minimally invasive surgical techniques or advanced biomaterials. Timeline: Ongoing.
• Geographic Expansion: Orthofix has the opportunity to expand its presence in emerging markets, such as Asia-Pacific and Latin America. These regions offer significant growth potential due to increasing healthcare spending and a growing demand for advanced medical technologies. By establishing partnerships with local distributors and investing in sales and marketing, Orthofix can penetrate these markets and drive revenue growth. Timeline: Ongoing.
• Technological Innovation: Investing in research and development to create innovative products can drive growth. This includes developing new materials, surgical techniques, and digital solutions that improve patient outcomes and reduce healthcare costs. Orthofix can collaborate with universities and research institutions to accelerate the development of new technologies. Timeline: Ongoing.

What Are OFIX's Competitive Advantages?

• Proprietary Technology: Orthofix has developed proprietary technologies in bone growth stimulation and regenerative biologics.
• Established Distribution Network: The company has an established network of direct sales representatives and independent distributors.
• Regulatory Expertise: Orthofix has expertise in navigating the regulatory requirements for medical devices in multiple countries.
• Strong Brand Reputation: Orthofix has built a strong brand reputation for quality and innovation in the medical device industry.

What Does OFIX Do?

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, is a global medical device and biologics company. Originally named Orthofix International N.V., the company rebranded in July 2018 to Orthofix Medical Inc. The company operates through two primary segments: Global Spine and Global Orthopedics. The Global Spine segment focuses on bone growth stimulator devices that enhance bone fusion and treat fractures. This segment also designs, develops, and markets motion preservation and fixation implant products used in spinal surgeries, along with regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment develops and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. Orthofix markets and distributes its products through a network of direct sales representatives, independent distributors, and employed sales representatives, reaching physicians, hospitals, ambulatory surgery centers, and integrated health delivery systems worldwide. The company's commitment to innovation and quality has established it as a key player in the medical device industry, serving patients across the United States, Italy, Germany, France, the United Kingdom, and Brazil.

What Products and Services Does OFIX Offer?

• Develops bone growth stimulator devices to enhance bone fusion.
• Manufactures and distributes spinal motion preservation and fixation implants.
• Markets regenerative non-tissue biologic solutions derived from synthetic materials.
• Designs and markets orthopedic products for fracture repair.
• Offers products for deformity correction and bone reconstruction procedures.
• Provides support services for its medical devices.

How Does OFIX Make Money?

• Develops and manufactures medical devices and biologics.
• Markets and distributes products through direct sales representatives and independent distributors.
• Generates revenue through the sale of spinal and orthopedic products.
• Provides support services and training to healthcare professionals.

What Industry Does OFIX Operate In?

Orthofix Medical Inc. operates in the competitive medical device industry, which is characterized by continuous innovation and stringent regulatory requirements. The global medical device market is expected to grow, driven by an aging population and increasing demand for advanced medical technologies. Orthofix competes with larger players in both the spine and orthopedics segments. The company's focus on specialized products and regenerative solutions positions it to capture niche markets within the broader industry. Key trends include the adoption of minimally invasive surgical techniques and the development of biocompatible materials.

Who Are OFIX's Key Customers?

• Physicians specializing in spine and orthopedic surgery.
• Hospitals and ambulatory surgery centers.
• Integrated health delivery systems.
• Other purchasing organizations in the healthcare sector.

Over the past six months, Orthofix Medical Inc. insiders filed 27 SEC Form 4 transactions — 5 sales and 22 purchases. On net that is roughly 561K shares acquired (about $4.8M) — insiders putting money in tends to read as conviction.

Wall Street analysts project Orthofix Medical Inc. revenue of about $848.6M for fiscal 2026, with EPS near $-1.17. The estimate reflects 4 contributing analysts.

Orthofix Medical Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 395.8% below estimates on average.

Orthofix Medical Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.13 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Orthofix Medical Inc. stands at -13.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.87 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.9%, the inverse of the P/E and a quick read on earnings relative to price.

Orthofix Medical Inc. (OFIX) Valuation Context

Valued at $405M, OFIX is classified as a small-cap stock. Relative to its peer group, OFIX's quantitative score of 33/100 is below the peer average of 80/100.

OFIX Revenue & Earnings Trend

In Q2 2026, OFIX generated $210.9M in top-line revenue, marking a sequential increase of 7.2%. The company recorded a net loss of $15.8M, with diluted EPS of $-0.39. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, OFIX averaged $-0.38 in diluted EPS.

Company Profile

Orthofix Medical Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Lewisville, US. The company is led by CEO Massimo Calafiore. OFIX has traded publicly since 1992.

OFIX Financials

OFIX Latest News

OFIX Analyst Consensus

OFIX MoonshotScore

Latest Orthofix Medical Inc. Analysis

OFIX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources